T‐DM1 resulted in greater growth inhibition than that with trastuzumab in the highest HER2‐expressing BC cell line, RT4V6, and improved antitumor effects in preclinical models of HER2‐overexpressing BC.141. Here, ERBB2 is linked to breast cancer.